Skip to main content

Table 1 Characteristics of plasma cohorts 1 and 2

From: Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis

Plasma cohort 1 Healthy subjects Patients with RA P value
 Female, n (%) 33 (78.6) 36 (81.8) ns
 Male, n (%) 9 (21.4) 8 (18.2) ns
 Age, yr (mean ± SEM) 60.9±0.8 61.83±2.1 ns
 TNF-α, pg/ml (median [IQR]) 75.0 [51.4–88.9] 87.8 [57.8–126.4] 0.0235
 PAF, ng/ml (mean ± SEM) 27.9±1.4 33.4±1.7 0.0185
Plasma cohort 2 ACPAneg patients with RA ACPApos patients with RA P value
 Female, n (%) 26 (78.8) 25 (75.8) ns
 Male, n (%) 7 (21.2) 8 (24.2) ns
 Age, yr (mean ± SEM) 56.0±2.8 55.6±2.6 ns
 DAS44 (mean ± SEM) 3.1±0.8 3.2±0.1 ns
 ACPA (AU/ml) (median [IQR]) 6.2 [2.6–14.6] 238.7 [98.4–1093] 0.0001
 RF IgM (median [IQR]) 1.0 [0.0–2.5] 23.0 [6.0–80.0] 0.0001
 TNF-α, pg/ml (mean ± SEM) 62.8±8.8 77.6±6.1 ns
 PAF, ng/ml (mean ± SEM) 146.1±11.5 120.9±9.7 ns
  1. ACPA anti-citrullinated protein antibodies, DAS44 Disease Activity Score in 44 joints, IgM immunoglobulin M, IQR interquartile range, ns not significant, PAF platelet-activating factor, RA rheumatoid arthritis, RF rheumatoid factor, TNF tumour necrosis factor